Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
Zi-Han Zhang, Qing-Xin Liu, Wen Zhang, Jing-Qin Ma, Jian-Hua Wang, Jian-Jun Luo, Ling-Xiao Liu, Zhi-Ping Yan, Department of Interventional Radiology, Zhongshan Hospital, Fudan University and Shanghai Institute of Medical Imaging, Shanghai 20032, China.
Author contributions: Ma JQ, Luo JJ and Yan ZP were involved in study conception and design; Zhang ZH and Zhang W acquired the data; Liu QX, Wang JH, and Liu LX analyzed and interpreted the data; All authors were involved in the drafting and critical revision of the manuscript and approved the final version of the manuscript.
Supported by the Project of Advanced and Appropriate Technique Generalization of Shanghai Health and Family Planning Committee, No. 2013SY060; and the Scientific Program of Shanghai Municipal Heath Bureau, No. 20124188.
Institutional review board statement: The study protocol was reviewed and approved by the institutional ethics committee of the respective hospital involved.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author, Dr. Jian-Jun Luo, at firstname.lastname@example.org.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jian-Jun Luo, MD, Department of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 20032, China. email@example.com
Received: August 17, 2017
Peer-review started: August 18, 2017
First decision: August 30, 2017
Revised: September 18, 2017
Accepted: October 17, 2017
Article in press: October 17, 2017
Published online: November 21, 2017